Dr. Schmoll on the Toxicity of the CHARTA Study in CRC

Hans-Joachim Schmoll, MD
Published: Tuesday, Oct 10, 2017



Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).

According to Schmoll, every patient with CRC who needs chemotherapy should receive FOLFOX and bevacizumab (Avastin) with irinotecan.

Overall, the toxicity of the combination was well tolerated. Additionally, there was no significant difference in the quality of life between both arms.
 
SELECTED
LANGUAGE


Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).

According to Schmoll, every patient with CRC who needs chemotherapy should receive FOLFOX and bevacizumab (Avastin) with irinotecan.

Overall, the toxicity of the combination was well tolerated. Additionally, there was no significant difference in the quality of life between both arms.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x